PURPOSE: To investigate if changes in tumor angiogenesis associated with complete pathologic response (pCR) or partial pathologic response (pPR) to treatment can be demonstrated by using diffuse optical spectroscopic (DOS) tomography. MATERIALS AND METHODS: All participants in this prospective, HIPAA-compliant, institutional review board-approved study provided written informed consent. Eleven women with invasive breast carcinoma were imaged with DOS tomography prior to, during, and at completion of neoadjuvant chemotherapeutic regimens. By using region of interest (ROI) analysis, the DOS measure of total tissue hemoglobin (Hb(T)) was temporally correlated with quantitative measures of existing (CD31-expressing) and tumor-induced (CD105-expressing) vessels, in pretreatment and posttreatment tissue specimens, to assess change. RESULTS: Quantified angiogenesis alone in pretreatment core biopsy specimens did not predict treatment response, but mean vessel density (MVD) and mean vessel area (MVA) of CD105-expressing vessels were significantly decreased in women with pCR (n = 7) (P < .001 and P = .003, respectively). MVA of CD105-expressing vessels was also significantly reduced at comparison of pre- and posttreatment residual tumor for women with pPR (n = 4) (P = .033). A longitudinal analysis showed significant decreases (P = .001) in mean Hb(T) levels during neoadjuvant chemotherapy in breast abnormality ROIs for women with pCR but not women with pPR. For women with pCR, but not women with pPR, pretreatment MVD of CD105-expressing vessels correlated with pretreatment Hb(T) (P ≤ .001). CONCLUSION: DOS tomographic examinations in women with breast cancer who are receiving neoadjuvant chemotherapy show a mean decrease in Hb(T) with time in patients with pCR only. Observed pretreatment and posttreatment correlates with quantified angiogenesis markers confirm the likely biologic origin for this DOS signature and support its potential to predict angiogenic tissue response early in the treatment cycle. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11100699/-/DC1. RSNA, 2011
PURPOSE: To investigate if changes in tumor angiogenesis associated with complete pathologic response (pCR) or partial pathologic response (pPR) to treatment can be demonstrated by using diffuse optical spectroscopic (DOS) tomography. MATERIALS AND METHODS: All participants in this prospective, HIPAA-compliant, institutional review board-approved study provided written informed consent. Eleven women with invasive breast carcinoma were imaged with DOS tomography prior to, during, and at completion of neoadjuvant chemotherapeutic regimens. By using region of interest (ROI) analysis, the DOS measure of total tissue hemoglobin (Hb(T)) was temporally correlated with quantitative measures of existing (CD31-expressing) and tumor-induced (CD105-expressing) vessels, in pretreatment and posttreatment tissue specimens, to assess change. RESULTS: Quantified angiogenesis alone in pretreatment core biopsy specimens did not predict treatment response, but mean vessel density (MVD) and mean vessel area (MVA) of CD105-expressing vessels were significantly decreased in women with pCR (n = 7) (P < .001 and P = .003, respectively). MVA of CD105-expressing vessels was also significantly reduced at comparison of pre- and posttreatment residual tumor for women with pPR (n = 4) (P = .033). A longitudinal analysis showed significant decreases (P = .001) in mean Hb(T) levels during neoadjuvant chemotherapy in breast abnormality ROIs for women with pCR but not women with pPR. For women with pCR, but not women with pPR, pretreatment MVD of CD105-expressing vessels correlated with pretreatment Hb(T) (P ≤ .001). CONCLUSION: DOS tomographic examinations in women with breast cancer who are receiving neoadjuvant chemotherapy show a mean decrease in Hb(T) with time in patients with pCR only. Observed pretreatment and posttreatment correlates with quantified angiogenesis markers confirm the likely biologic origin for this DOS signature and support its potential to predict angiogenic tissue response early in the treatment cycle. SUPPLEMENTAL MATERIAL: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.11100699/-/DC1. RSNA, 2011
Authors: Regine Choe; Alper Corlu; Kijoon Lee; Turgut Durduran; Soren D Konecky; Monika Grosicka-Koptyra; Simon R Arridge; Brian J Czerniecki; Douglas L Fraker; Angela DeMichele; Britton Chance; Mark A Rosen; Arjun G Yodh Journal: Med Phys Date: 2005-04 Impact factor: 4.071
Authors: Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton Journal: AJR Am J Roentgenol Date: 2005-06 Impact factor: 3.959
Authors: Xin Wang; Brian W Pogue; Shudong Jiang; Hamid Dehghani; Xiaomei Song; Subhadra Srinivasan; Ben A Brooksby; Keith D Paulsen; Christine Kogel; Steven P Poplack; Wendy A Wells Journal: J Biomed Opt Date: 2006 Jul-Aug Impact factor: 3.170
Authors: Subhadra Srinivasan; Brian W Pogue; Shudong Jiang; Hamid Dehghani; Christine Kogel; Sandra Soho; Jennifer J Gibson; Tor D Tosteson; Steven P Poplack; Keith D Paulsen Journal: Acad Radiol Date: 2006-02 Impact factor: 3.173
Authors: Sina Meisamy; Patrick J Bolan; Eva H Baker; Robin L Bliss; Evin Gulbahce; Lenore I Everson; Michael T Nelson; Tim H Emory; Todd M Tuttle; Douglas Yee; Michael Garwood Journal: Radiology Date: 2004-11 Impact factor: 11.105
Authors: Lisa A Carey; Richard Metzger; E Claire Dees; Frances Collichio; Carolyn I Sartor; David W Ollila; Nancy Klauber-DeMore; Jan Halle; Lynda Sawyer; Dominic T Moore; Mark L Graham Journal: J Natl Cancer Inst Date: 2005-08-03 Impact factor: 13.506
Authors: D J Manton; A Chaturvedi; A Hubbard; M J Lind; M Lowry; A Maraveyas; M D Pickles; D J Tozer; L W Turnbull Journal: Br J Cancer Date: 2006-02-13 Impact factor: 7.640
Authors: Elizabeth M C Hillman; Cyrus B Amoozegar; Tracy Wang; Addason F H McCaslin; Matthew B Bouchard; James Mansfield; Richard M Levenson Journal: Philos Trans A Math Phys Eng Sci Date: 2011-11-28 Impact factor: 4.226
Authors: Shigeto Ueda; Darren Roblyer; Albert Cerussi; Amanda Durkin; Anais Leproux; Ylenia Santoro; Shanshan Xu; Thomas D O'Sullivan; David Hsiang; Rita Mehta; John Butler; Bruce J Tromberg Journal: Cancer Res Date: 2012-07-09 Impact factor: 12.701
Authors: Kelly E Michaelsen; Venkataramanan Krishnaswamy; Adele Shenoy; Emily Jordan; Brian W Pogue; Keith D Paulsen Journal: J Biomed Opt Date: 2014-02 Impact factor: 3.170
Authors: Paul M Meaney; Amir H Golnabi; Neil R Epstein; Shireen D Geimer; Margaret W Fanning; John B Weaver; Keith D Paulsen Journal: Med Phys Date: 2013-10 Impact factor: 4.071
Authors: Gabriel Ramirez; Ashley R Proctor; Ki Won Jung; Tong Tong Wu; Songfeng Han; Russell R Adams; Jingxuan Ren; Daniel K Byun; Kelley S Madden; Edward B Brown; Thomas H Foster; Parisa Farzam; Turgut Durduran; Regine Choe Journal: Biomed Opt Express Date: 2016-08-24 Impact factor: 3.732
Authors: Bruce J Tromberg; Zheng Zhang; Anaïs Leproux; Thomas D O'Sullivan; Albert E Cerussi; Philip M Carpenter; Rita S Mehta; Darren Roblyer; Wei Yang; Keith D Paulsen; Brian W Pogue; Shudong Jiang; Peter A Kaufman; Arjun G Yodh; So Hyun Chung; Mitchell Schnall; Bradley S Snyder; Nola Hylton; David A Boas; Stefan A Carp; Steven J Isakoff; David Mankoff Journal: Cancer Res Date: 2016-08-15 Impact factor: 12.701